NCT02020629已完成4 期
Effect of Lixisenatide on Glucagon Secretion During Hypoglycemia in Patients With Insulin-treated Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Glucagon response to hypoglycemia
研究概览
简要总结
In hypoglycemia, there is a counterregulation to restore glucose levels. An important part of this counterregulation is the release of the hormone glucagon. Since the GLP-1 receptor agonist lixisenatide has been shown to be associated with a low risk of hypoglycemia, this study examines whether lixisenatide affects the glucagon response to hypoglycemia.
详细描述
The study is a single-center, randomized, placebo-controlled study with a cross-over design and examines the glucagon response during a hyperinsulinemic hypoglycemic phase after a 6-week treatment with lixisenatide (or placebo) as add-on to basal insulin and metformin. The hypothesis of the study is that the glucagon counterregulation to hypoglycemia in patients treated with lixisenatide and basal insulin is not lower than in patients treated with basal insulin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male, non-fertile female or female of childbearing potential using a medically approved birth control method aged >18 years.
- •Adult patients with type 2 diabetes treated with basal insulin (NPH insulin, insulin detemir, insulin glargine or insulin degludec) (stable insulin dose (±10%) during the last three months) with concomitant at >3 months stable dose (>1500 mg daily) of metformin.
- •HbA1c <10% (DCCT standard; < 83 mmol(mol) at visit 1.
排除标准
- •Treatment with antihyperglycemic agents apart from basal insulin and metformin, i.e., bolus insulin or other antihyperglycemic oral agents apart from metformin
- •Type 1 diabetes (including LADA)
- •Pregnant or lactating female. Women of childbearing potential with no effective contraceptive method. Acceptable contraceptive include contraceptive sponge; hormonal contraception pills, patches, vaginal rings, injectable contraceptives; and intrauterine devices. Women of childbearing potential (pre-menopausal, not surgically sterile women for at least 3 months prior to the time of screening) must have a confirmed negative serum pregnancy test at screening visit. They must use an effective contraceptive method throughout the study, and agree to repeat pregnancy tests at designated visits. The applied methods of contraception have to meet the criteria for a highly effective method of birth control according to the "Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals (CPMP/ICH/286/95)"
- •A history of any secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.
- •Acute infections which may affect blood glucose control within 4 weeks prior to visit 1
- •Any history of recent (<2 weeks) recurrent or severe hypoglycemic episodes or hypoglycemia unawareness
- •Donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks.
- •Treatment with growth hormone and oral or parenteral corticosteroid (> 7 consecutive days of treatment) within 8 weeks prior to visit 1 and thereafter during the whole study period.
- •Use of other investigational drugs within 30 days prior to visit
- •Laboratory findings at the time of screening, including amylase and/or lipase > 3 times the upper limit of the normal laboratory range (ULN) and P-calcitonin ≥20 pg/ml (5.9 pmol/L).
- •Personal or immediate family history of medullary thyroid cancer (MTC) or genetic condition that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes).
- •History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery
- •Allergic reaction to any GLP-1 receptor agonist or to metacresol
- •Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting,
- •Cardiovascular, hepatic, neurological, or endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult.
研究组 & 干预措施
Lixisenatide
Experimental
Lixisenatide 20µg daily
干预措施: Lixisenatide (Drug)
结局指标
主要结局
Glucagon response to hypoglycemia
时间窗: 30 min
Hypoglycemia is induced by clamp during 30 min; glucagon levels are measured during this time frame
次要结局
- Cortisol response to hypoglycemia(30 min)
- Catecholamines(30 min)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy PeopleDiabetes MellitusGastroparesisNCT02308254Royal Adelaide Hospital30
已完成
不适用
The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised SubjectsDiabetes After Total PancreatectomyNCT02640118University Hospital, Gentofte, Copenhagen24
已完成
3 期
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- MetforminType 2 Diabetes MellitusNCT01632163Sanofi447
已完成
4 期
Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 DiabetesType 2 DiabetesNCT02049034University of Surrey8
已完成
3 期
Liraglutide in Adolescents With Type 1 DiabetesType 1 DiabetesNCT02516657University at Buffalo5